Why Did Cathie Wood Buy AMD?
Noted tech investor Cathie Wood has used the recent stock…
Sell
33
APLS Quote, Financials, Valuation and Earnings
Last price:
$20.36
Seasonality move
:
-4.11%
Day range:
$20.09 - $20.75
52-week range:
$16.98 - $49.06
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.23x
P/B ratio:
11.17x
Volume:
2.2M
Avg. volume:
2.7M
1-year change:
-57.17%
Market cap:
$2.6B
Revenue:
$781.4M
EPS (TTM):
-$1.59
Analysts' Opinion
-
Consensus RatingApellis Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 8 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $41.50, Apellis Pharmaceuticals has an estimated upside of 104.03% from its current price of $20.34.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $21.00 representing 100% downside risk from its current price of $20.34.
Fair Value
-
According to the consensus of 19 analysts, Apellis Pharmaceuticals has 104.03% upside to fair value with a price target of $41.50 per share.
APLS vs. S&P 500
-
Over the past 5 trading days, Apellis Pharmaceuticals has overperformed the S&P 500 by 12.99% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Apellis Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Apellis Pharmaceuticals has grown year-over-year revenues for 8 quarters straight. In the most recent quarter Apellis Pharmaceuticals reported revenues of $212.5M.
Earnings Growth
-
Apellis Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Apellis Pharmaceuticals reported earnings per share of -$0.29.
Enterprise value:
2.6B
EV / Invested capital:
--
Price / LTM sales:
3.23x
EV / EBIT:
--
EV / Revenue:
3.32x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-29.39x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$663.6M
Return On Assets:
-22.95%
Net Income Margin (TTM):
-25.33%
Return On Equity:
-83.06%
Return On Invested Capital:
-36.11%
Operating Margin:
-12.31%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $75.4M | $396.6M | $781.4M | $146.4M | $212.5M | |
| Gross Profit | $69.8M | $338.1M | $663.6M | $126.5M | $171.7M | |
| Operating Income | -$594.6M | -$517.1M | -$165M | -$84.5M | -$26.2M | |
| EBITDA | -$617.3M | -$495.1M | -$154.5M | -$79.2M | -$24.1M | |
| Diluted EPS | -$6.13 | -$4.48 | -$1.59 | -$0.73 | -$0.29 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $917.2M | $824M | $719.5M | $766.3M | $789M | |
| Total Assets | $960.6M | $881.8M | $760.2M | $788.7M | $885.1M | |
| Current Liabilities | $128.3M | $131.8M | $167.6M | $247.6M | $185.5M | |
| Total Liabilities | $756M | $683.1M | $590.3M | $594.2M | $656.5M | |
| Total Equity | $204.6M | $198.7M | $169.9M | $194.5M | $228.5M | |
| Total Debt | $358.8M | $189M | $92.7M | $93M | $452.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$513.7M | -$594.7M | -$87.9M | -$97.9M | $19.4M | |
| Cash From Investing | $59.9M | -$674K | -$403K | $4K | -$20K | |
| Cash From Financing | $365.7M | $394.5M | $149.2M | -$3.9M | -$4M | |
| Free Cash Flow | -$515.3M | -$595.5M | -$88.3M | -$98M | $19.3M | |
APLS
Sector
Market Cap
$2.6B
$35.8M
Price % of 52-Week High
41.46%
45.38%
Dividend Yield
0%
0%
Shareholder Yield
-1.81%
-0.81%
1-Year Price Total Return
-57.17%
-38.89%
Beta (5-Year)
0.725
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$18.54
200-day SMA
Sell
Level
$30.10
Bollinger Bands (100)
Sell
Level
21.58 - 32.08
Chaikin Money Flow
Sell
Level
-23.5M
20-day SMA
Buy
Level
$18.73
Relative Strength Index (RSI14)
Buy
Level
52.15
ADX Line
Buy
Level
37.46
Williams %R
Sell
Level
-10.8609
50-day SMA
Sell
Level
$22.43
MACD (12, 26)
Sell
Level
-0.98
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Sell
Level
-56.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.0526)
Sell
CA Score
(Annual)
Level (-2.0757)
Sell
Beneish M-Score
(Annual)
Level (18.131)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.1882)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Stock Forecast FAQ
In the current month, APLS has received 11 Buy ratings 8 Hold ratings, and 0 Sell ratings. The APLS average analyst price target in the past 3 months is $41.50.
-
Where Will Apellis Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Apellis Pharmaceuticals share price will rise to $41.50 per share over the next 12 months.
-
What Do Analysts Say About Apellis Pharmaceuticals?
Analysts are divided on their view about Apellis Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Apellis Pharmaceuticals is a Sell and believe this share price will drop from its current level to $21.00.
-
What Is Apellis Pharmaceuticals's Price Target?
The price target for Apellis Pharmaceuticals over the next 1-year time period is forecast to be $41.50 according to 19 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is APLS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Apellis Pharmaceuticals is a Buy. 11 of 19 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of APLS?
You can purchase shares of Apellis Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Apellis Pharmaceuticals shares.
-
What Is The Apellis Pharmaceuticals Share Price Today?
Apellis Pharmaceuticals was last trading at $20.36 per share. This represents the most recent stock quote for Apellis Pharmaceuticals. Yesterday, Apellis Pharmaceuticals closed at $20.34 per share.
-
How To Buy Apellis Pharmaceuticals Stock Online?
In order to purchase Apellis Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Salesforce Stock Drop After a Strong Quarter?
Popular customer relationship management platform provider Salesforce (NYSE:CRM) has been…
Is Adobe Stock a Bargain With AI Tools Driving Growth?
The share price of American computer software company Adobe (NASDAQ:ADBE)…
Stock Ideas
Buy
71
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
4
CABO alert for May 3
Cable One [CABO] is down 41.98% over the past day.
Buy
55
PDEX alert for May 3
Pro-Dex [PDEX] is down 32.02% over the past day.
Buy
91
TRUP alert for May 3
Trupanion [TRUP] is up 23.52% over the past day.
